You'd be wrong about that... If SAVA, or another biotech, improved QOL for Rett girls and reduced seizures, I'd be positive about its prospects, regardless if the endpoints were barely missed... and likely would invest on the overreacted price takedown. It's about the big picture, not the p-values.
In spite of the near miss for Rett, Anavex is doing just fine... and will have approval for blarcamesine this year.
News 
Market Data 
Discover 
